Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Artiva Biotherapeutics, Inc. (ARTV : NSDQ)

• Company Description    Artiva Biotherapeutics Inc. is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company's lead program includes AlloNK(R). Artiva Biotherapeutics Inc. is based in SAN DIEGO. Number of Employees: 89

• Price / Volume Information    Yesterday's Closing Price: $1.79 Daily Weekly Monthly 20 Day Moving Average: 319,408 shares Shares Outstanding: 24.36 (millions) Market Capitalization: $43.61 (millions) Beta: 52 Week High: $17.31 52 Week Low: $1.47 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.68% -15.95% 12 Week -20.09% -32.78% Year To Date -82.24% -83.37%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5505 MOREHOUSE DRIVE - SAN DIEGO,CA 92121 USA ph: 858-267-4467 fax: - ir@artivabio.com http://www.artivabio.com

• General Corporate Information    Officers Fred Aslan - President and Chief Executive Officer Brian Daniels - Director and Board Chair Neha Krishnamohan - Chief Financial Officer and EVP; Corporate Develop Laura Bessen - Director Elizabeth Hougen - Director Peer Information Artiva Biotherapeutics, Inc. (CORR.) Artiva Biotherapeutics, Inc. (RSPI) Artiva Biotherapeutics, Inc. (CGXP) Artiva Biotherapeutics, Inc. (BGEN) Artiva Biotherapeutics, Inc. (GTBP) Artiva Biotherapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04317A107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 09/04/25 Share - Related Items Shares Outstanding: 24.36 Most Recent Split Date: (:1) Beta: Market Capitalization: $43.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.84 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.32 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.26 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -75.95 12/31/24 - -128.26 ROA 06/30/25 - - 03/31/25 - -39.51 12/31/24 - -49.32 Current Ratio 06/30/25 - - 03/31/25 - 13.93 12/31/24 - 15.40 Quick Ratio 06/30/25 - - 03/31/25 - 13.93 12/31/24 - 15.39 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -26,045.02 Book Value 06/30/25 - - 03/31/25 - 6.93 12/31/24 - 7.68 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.01 12/31/24 - 0.02

Powered by Zacks Investment Research ©